Lancet Impact Factor 2026: 88.5 | Trend, Acceptance Rate & What Lancet Publishes

The Lancet is the second-highest impact factor medical journal in the world, behind only NEJM. Its IF of 88.5 in 2024 reflects a combination of high citation volume from landmark clinical trials, systematic reviews, and the journal's dominant position in global health research. For clinical researchers, understanding what Lancet specifically publishes: and what it doesn't: is more useful than the IF number alone.

Impact factor trend

The 2021 spike to 202.7 was almost entirely driven by COVID-19 research. The Lancet published several of the most-cited pandemic papers in 2020-2021, including early clinical trial data on COVID-19 treatments and landmark epidemiological studies. As those papers aged out of the 2-year citation window, the IF normalized. The current 88.5 reflects pre-COVID baseline trends with continued growth.

What Lancet editors specifically require

The Lancet's editorial criteria differ from NEJM and JAMA in one important way: global relevance is explicitly stated as an editorial priority, not just implicit.

From Lancet's own author guidelines: the journal prioritizes research with implications beyond high-income countries. A randomized trial conducted entirely in a US tertiary care center, with findings applicable only to that population, is a harder sell than the same trial with a diverse international cohort or explicit analysis of generalizability to lower-resource settings.

This doesn't mean The Lancet only publishes global health research. It publishes landmark clinical trials from high-income settings regularly. But it does mean the framing matters. If your study has relevance to global practice, make that explicit in the cover letter and discussion.

Acceptance rate breakdown

The Lancet's acceptance rate sits below 5% across all submissions:

• ~60-70% desk rejected in 1-2 weeks
• ~15-20% sent to external review
• ~5% ultimately accepted

Desk rejection at The Lancet is predominantly scope-based. Papers that are strong clinical research but lack the "changes practice globally" framing get cut before external review. Papers with regional focus and no attempt to address generalizability are a common desk rejection type.

Among papers that reach external review, the acceptance rate is roughly 20-30%. Getting to external review at The Lancet is itself a meaningful signal.

Review timeline

Lancet revision requests are substantive. First major revisions typically ask for additional analyses, subgroup data, or expanded discussion of generalizability. Budget 2-4 months for a thorough revision response.

What types of papers get published

The most common published formats in The Lancet:

Large randomized controlled trials: multicenter, international, with primary endpoints that would change clinical practice. Phase 3 trials meeting this bar are the highest-acceptance category.

Systematic reviews and meta-analyses: large-scale reviews of clinical interventions or disease burden. The Cochrane-style systematic review with direct practice implications is a strong fit.

Global burden of disease studies: epidemiological analyses of disease prevalence, incidence, or mortality with country-level or global scope. These form a significant portion of Lancet content.

Health policy analyses: studies examining healthcare systems, access, or outcomes with policy implications. The Lancet publishes more health policy content than any comparable medical journal.

Original research with multinational cohorts: trials or observational studies with international recruitment, improving generalizability.

How Lancet compares to NEJM

For clinical researchers outside the US, The Lancet is often the stronger target. For US clinical trials with practice implications primarily relevant to the American healthcare system, NEJM may be the better fit. Both should be on the shortlist for any landmark clinical study.

Practical submission checklist

• [ ] Global or multi-country relevance is explicit in cover letter and discussion
• [ ] Study design is appropriate for the clinical question (RCT, systematic review, or cohort)
• [ ] Primary endpoints are clinically meaningful, not surrogate markers without validation
• [ ] Statistical analysis plan was pre-specified (if applicable)
• [ ] CONSORT, PRISMA, or STROBE reporting checklist completed
• [ ] Subgroup analyses pre-specified and clearly labeled as exploratory vs. primary
• [ ] Ethics approval and trial registration documented
• [ ] Data sharing statement with specific access instructions
• [ ] Cover letter addresses how findings would change practice beyond high-income settings
• [ ] Competing interests declared for all authors

Sources and further reading

Impact factor data from Clarivate Journal Citation Reports (released June 2025). For submission guidelines, see the Lancet author information.

See our full Lancet journal guide for editorial scope and submission requirements. For manuscript preparation, see our avoid desk rejection service.

• NEJM impact factor guide: IF 78.5, comparison with The Lancet
• JAMA impact factor guide: IF 55.0, the third major general medical journal
• Lancet Oncology impact factor guide: IF 35.9, the oncology-focused Lancet journal
• Cover letter templates: clinical/medical journal template

How The Lancet's IF Has Changed Over Time

The 2021 spike to 202.7 was entirely driven by COVID-19 research. Landmark papers on vaccines, variants, and pandemic epidemiology generated thousands of citations in a compressed window. The IF has since declined toward its pre-pandemic baseline.

For hiring and grant evaluation purposes, 88.5 is a more representative number for what a Lancet publication signals. The 2021-2022 numbers inflate historical comparisons with publications from that period.

How The Lancet Compares to Other Major Medical Journals

The Lancet's particular strength is global health and clinical medicine with a global equity angle. Papers that address health disparities, low-resource clinical settings, or global disease burden often do better at The Lancet than at NEJM, which skews more toward North American clinical practice.

What The Lancet Looks For

The Lancet publishes clinical research that changes practice or frames major public health questions. The evidence bar is high: randomized trials, large prospective cohort studies, or systematic reviews that definitively answer contested clinical questions.

The journal is also more receptive than NEJM to commentary, perspectives, and high-profile correspondence , making it one of the few high-IF journals where a well-crafted perspective piece on a major health issue can be published without a clinical trial behind it.

For the primary research bar: think landmark trials that affect patient populations in the tens or hundreds of millions. If your study is practice-changing for a specific specialty or a defined population, Lancet specialty journals (Lancet Oncology, Lancet Neurology, Lancet Infectious Diseases) are often the better fit.

When The Lancet Is the Right Target (and When It Isn't)

The Lancet is the right target for clinical research that matters globally, not just within a specialty. If your trial's findings would change practice in 50 countries rather than just one health system, The Lancet is the appropriate venue.

It's not the right target for specialty-specific clinical work that primarily affects a defined subspecialty. Those papers , even landmark ones , typically belong in the relevant Lancet specialty journal or the leading specialty-specific journal. A landmark oncology trial goes to Lancet Oncology or JCO, not The Lancet itself, unless its implications span multiple cancer types or the entire cancer care system.

The Bottom Line

The Lancet at 88.5 is the right target for high-impact clinical research with direct implications for medical practice. The 6% acceptance rate reflects that standard. Before you submit, your paper's framing and scope need to be as strong as its data , editors read the cover letter and abstract before the methods.

See also

• How to avoid desk rejection
• Pre-submission checklist